Aquestive Therapeutics Stock Buy Hold or Sell Recommendation
| AQST Stock | USD 2.84 0.12 4.41% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Aquestive Therapeutics is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Aquestive Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Aquestive Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Aquestive Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide. Note, we conduct extensive research on individual companies such as Aquestive and provide practical buy, sell, or hold advice based on investors' constraints. Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Aquestive |
Execute Aquestive Therapeutics Buy or Sell Advice
The Aquestive recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Aquestive Therapeutics. Macroaxis does not own or have any residual interests in Aquestive Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Aquestive Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Aquestive Therapeutics Trading Alerts and Improvement Suggestions
| Aquestive Therapeutics generated a negative expected return over the last 90 days | |
| Aquestive Therapeutics has high historical volatility and very poor performance | |
| Aquestive Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Aquestive Therapeutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 57.56 M. Net Loss for the year was (44.14 M) with profit before overhead, payroll, taxes, and interest of 39.69 M. | |
| Aquestive Therapeutics currently holds about 17.7 M in cash with (35.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Latest headline from insidermonkey.com: Disposition of 2182 shares by Cassie Jung of Aquestive Therapeutics at 2.54 subject to Rule 16b-3 |
Aquestive Therapeutics Returns Distribution Density
The distribution of Aquestive Therapeutics' historical returns is an attempt to chart the uncertainty of Aquestive Therapeutics' future price movements. The chart of the probability distribution of Aquestive Therapeutics daily returns describes the distribution of returns around its average expected value. We use Aquestive Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Aquestive Therapeutics returns is essential to provide solid investment advice for Aquestive Therapeutics.
| Mean Return | -0.49 | Value At Risk | -7.48 | Potential Upside | 6.23 | Standard Deviation | 4.31 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Aquestive Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Aquestive Stock Institutional Investors
The Aquestive Therapeutics' institutional investors refer to entities that pool money to purchase Aquestive Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 736.9 K | Bank Of America Corp | 2024-12-31 | 690.3 K | Essex Investment Management Company, Llc | 2024-12-31 | 623.3 K | Northern Trust Corp | 2024-12-31 | 599.8 K | Pale Fire Capital Se | 2024-12-31 | 525.8 K | Bracebridge Capital, Llc | 2024-12-31 | 459.2 K | Ubs Group Ag | 2024-12-31 | 420.6 K | Woodline Partners Lp | 2024-12-31 | 409.3 K | Everstar Asset Management Llc | 2024-09-30 | 400.1 K | Bratton Capital Management, L.p. | 2024-12-31 | 9.8 M | Blackrock Inc | 2024-12-31 | 6 M |
Aquestive Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | 398K | (1.6M) | (1.7M) | (989K) | 725K | 761.3K | |
| Investments | (517K) | (913K) | (2.5M) | (995K) | (159K) | (167.0K) | |
| Change In Cash | (17.5M) | (3.8M) | (751K) | (3.4M) | 47.7M | 50.1M | |
| Depreciation | 3.4M | 3.0M | 2.4M | 1.3M | 718K | 682.1K | |
| Capital Expenditures | 517K | 913K | 2.5M | 995K | 159K | 151.1K | |
| Net Income | (55.8M) | (70.5M) | (54.4M) | (7.9M) | (44.1M) | (46.3M) | |
| Change To Netincome | 35.3M | 12.3M | 6.8M | 20.3M | 23.4M | 11.8M | |
| End Period Cash Flow | 31.8M | 28.0M | 27.3M | 23.9M | 71.5M | 36.4M | |
| Free Cash Flow | (46.0M) | (33.9M) | (12.3M) | (7.4M) | (35.9M) | (37.7M) | |
| Other Non Cash Items | 4.7M | 15.7M | 5.8M | 2.8M | 10.5M | 6.2M |
Aquestive Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Aquestive Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Aquestive Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Aquestive stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.4 | |
β | Beta against Dow Jones | 0.96 | |
σ | Overall volatility | 4.39 | |
Ir | Information ratio | -0.09 |
Aquestive Therapeutics Volatility Alert
Aquestive Therapeutics exhibits very low volatility with skewness of 0.75 and kurtosis of 1.63. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Aquestive Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Aquestive Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Aquestive Therapeutics Fundamentals Vs Peers
Comparing Aquestive Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Aquestive Therapeutics' direct or indirect competition across all of the common fundamentals between Aquestive Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Aquestive Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Aquestive Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Aquestive Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Aquestive Therapeutics to competition |
| Fundamentals | Aquestive Therapeutics | Peer Average |
| Return On Asset | -0.24 | -0.14 |
| Profit Margin | (0.77) % | (1.27) % |
| Operating Margin | (1.14) % | (5.51) % |
| Current Valuation | 247.75 M | 16.62 B |
| Shares Outstanding | 98.87 M | 571.82 M |
| Shares Owned By Insiders | 5.04 % | 10.09 % |
| Shares Owned By Institutions | 48.31 % | 39.21 % |
| Number Of Shares Shorted | 9.98 M | 4.71 M |
| Price To Earning | (1.90) X | 28.72 X |
| Price To Sales | 4.88 X | 11.42 X |
| Revenue | 57.56 M | 9.43 B |
| Gross Profit | 39.69 M | 27.38 B |
| EBITDA | (26.62 M) | 3.9 B |
| Net Income | (44.14 M) | 570.98 M |
| Cash And Equivalents | 17.7 M | 2.7 B |
| Cash Per Share | 0.33 X | 5.01 X |
| Total Debt | 38 M | 5.32 B |
| Debt To Equity | 468.20 % | 48.70 % |
| Current Ratio | 1.47 X | 2.16 X |
| Book Value Per Share | (0.66) X | 1.93 K |
| Cash Flow From Operations | (35.76 M) | 971.22 M |
| Short Ratio | 4.93 X | 4.00 X |
| Earnings Per Share | (0.51) X | 3.12 X |
| Target Price | 9.86 | |
| Number Of Employees | 142 | 18.84 K |
| Beta | 2.76 | -0.15 |
| Market Capitalization | 280.79 M | 19.03 B |
| Total Asset | 101.42 M | 29.47 B |
| Retained Earnings | (363.21 M) | 9.33 B |
| Working Capital | 69.36 M | 1.48 B |
| Current Asset | 38.38 M | 9.34 B |
| Current Liabilities | 17.95 M | 7.9 B |
| Net Asset | 101.42 M |
Note: Disposition of 29307 shares by Daniel Barber of Aquestive Therapeutics at 2.65 subject to Rule 16b-3 [view details]
Aquestive Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Aquestive . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Aquestive Therapeutics Buy or Sell Advice
When is the right time to buy or sell Aquestive Therapeutics? Buying financial instruments such as Aquestive Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Aquestive Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Diversified Assets Thematic Idea Now
Diversified Assets
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.